Business Description
Omeros Corp
NAICS : 325412
SIC : 2834
ISIN : US6821431029
Share Class Description:
OMER: Ordinary SharesTotal Employee Number:
175Description
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.91 | |||||
Equity-to-Asset | -0.22 | |||||
Debt-to-Equity | -2.35 | |||||
Debt-to-EBITDA | -6.41 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -1.36 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 8.7 | |||||
3-Year EPS without NRI Growth Rate | 19.5 | |||||
3-Year FCF Growth Rate | -9.8 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.31 | |||||
9-Day RSI | 47.09 | |||||
14-Day RSI | 44.96 | |||||
3-1 Month Momentum % | 11.74 | |||||
6-1 Month Momentum % | -33.37 | |||||
12-1 Month Momentum % | 245 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.03 | |||||
Quick Ratio | 3.03 | |||||
Cash Ratio | 2.28 | |||||
Days Inventory | 113.79 | |||||
Days Sales Outstanding | 259.56 | |||||
Days Payable | 4462.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.5 | |||||
Shareholder Yield % | 2.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.07 | |||||
Operating Margin % | -1063.86 | |||||
Net Margin % | 871.02 | |||||
EBITDA Margin % | -234.84 | |||||
FCF Margin % | -958.08 | |||||
OCF Margin % | -957.84 | |||||
ROE % | Neg. Equity | |||||
ROA % | 34.94 | |||||
ROIC % | -60.06 | |||||
3-Year ROIIC % | -20.35 | |||||
ROC (Joel Greenblatt) % | -175.39 | |||||
ROCE % | -14.27 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.15 | |||||
Forward PE Ratio | 15.73 | |||||
Price-to-Owner-Earnings | 7.2 | |||||
PS Ratio | 90.05 | |||||
EV-to-EBIT | -30.25 | |||||
EV-to-EBITDA | -31.44 | |||||
EV-to-Revenue | 73.83 | |||||
EV-to-Forward-Revenue | 9.31 | |||||
EV-to-FCF | -7.71 | |||||
Earnings Yield (Greenblatt) % | -3.31 | |||||
FCF Yield % | -13.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OMER
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Omeros Corp Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.893 | ||
| EPS (TTM) ($) | 0.7 | ||
| Beta | 3.9092 | ||
| 3-Year Sharpe Ratio | 0.67 | ||
| 3-Year Sortino Ratio | 1.65 | ||
| Volatility % | 124.7 | ||
| 14-Day RSI | 44.96 | ||
| 14-Day ATR ($) | 0.957045 | ||
| 20-Day SMA ($) | 9.9765 | ||
| 12-1 Month Momentum % | 245 | ||
| 52-Week Range ($) | 2.95 - 17.65 | ||
| Shares Outstanding (Mil) | 72.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Omeros Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Omeros Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 137 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 136 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:30 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 45 days | ||
| General meeting for 2026 | 2026-06-18 10:00 | 9.64 (+2.12%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 16:30 | 14.76 (+1.10%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 14.76 (+1.10%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-31 16:30 | 9.81 (-1.41%) | ||
| Annual report for 2025 | 2026-03-31 | 9.81 (-1.41%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 9.81 (-1.41%) |
Show
Entries
Omeros Corp Frequently Asked Questions
What is Omeros Corp(OMER)'s stock price today?
The current price of OMER is $9.90. The 52 week high of OMER is $17.65 and 52 week low is $2.95.
When is next earnings date of Omeros Corp(OMER)?
The next earnings date of Omeros Corp(OMER) is 2026-08-14 Est..
Does Omeros Corp(OMER) pay dividends? If so, how much?
Omeros Corp(OMER) does not pay dividend.
Guru Commentaries on NAS:OMER
No articles.
Press Release
Articles on Omeros Corp
No articles.
Headlines
See More- 1
Jun 26, 2026
Acadia rises as EU backs Rett syndrome therapy
Seeking Alpha • 10:22am
Omeros drops as transplant therapy faces EU hurdle
Seeking Alpha • 7:54am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers